An­ti­body mak­er Vac­cinex files $46M IPO tout­ing I/O com­bo drug; Replimune shoots for $100M-plus in IPO

→ Af­ter spend­ing over a decade build­ing out a pipeline of an­ti­body drugs to treat can­cer, neu­ro­log­i­cal and au­toim­mune dis­eases, Vac­cinex is rid­ing on this …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER